Compare Novartis with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ALEMBIC LTD - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS ALEMBIC LTD NOVARTIS/
ALEMBIC LTD
 
P/E (TTM) x 505.3 63.8 791.9% View Chart
P/BV x 28.3 2.6 1,086.9% View Chart
Dividend Yield % 1.6 0.4 398.5%  

Financials

 NOVARTIS   ALEMBIC LTD
EQUITY SHARE DATA
    NOVARTIS
Mar-19
ALEMBIC LTD
Mar-18
NOVARTIS/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs98072 1,361.1%   
Low Rs60034 1,770.5%   
Sales per share (Unadj.) Rs198.74.7 4,227.9%  
Earnings per share (Unadj.) Rs21.06.1 343.5%  
Cash flow per share (Unadj.) Rs22.36.2 356.4%  
Dividends per share (Unadj.) Rs10.000.20 5,000.0%  
Dividend yield (eoy) %1.30.4 335.1%  
Book value per share (Unadj.) Rs307.540.7 756.2%  
Shares outstanding (eoy) m24.69267.03 9.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.011.3 35.3%   
Avg P/E ratio x37.78.7 434.4%  
P/CF ratio (eoy) x35.58.5 418.7%  
Price / Book Value ratio x2.61.3 197.3%  
Dividend payout %47.73.3 1,455.5%   
Avg Mkt Cap Rs m19,50814,139 138.0%   
No. of employees `0000.6NA-   
Total wages/salary Rs m1,171207 564.7%   
Avg. sales/employee Rs Th8,445.4NM-  
Avg. wages/employee Rs Th2,015.7NM-  
Avg. net profit/employee Rs Th891.0NM-  
INCOME DATA
Net Sales Rs m4,9071,255 390.9%  
Other income Rs m783370 211.4%   
Total revenues Rs m5,6891,625 350.0%   
Gross profit Rs m123111 110.5%  
Depreciation Rs m3238 84.1%   
Interest Rs m162 935.3%   
Profit before tax Rs m858442 194.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m34024 1,419.6%   
Profit after tax Rs m5181,630 31.8%  
Gross profit margin %2.58.9 28.3%  
Effective tax rate %39.65.4 731.2%   
Net profit margin %10.6129.8 8.1%  
BALANCE SHEET DATA
Current assets Rs m8,0551,867 431.4%   
Current liabilities Rs m1,850591 312.9%   
Net working cap to sales %126.4101.6 124.4%  
Current ratio x4.43.2 137.9%  
Inventory Days Days4594 47.8%  
Debtors Days Days3474 46.1%  
Net fixed assets Rs m1501,791 8.4%   
Share capital Rs m123534 23.1%   
"Free" reserves Rs m7,46910,324 72.3%   
Net worth Rs m7,59210,858 69.9%   
Long term debt Rs m041 0.0%   
Total assets Rs m9,82411,591 84.8%  
Interest coverage x54.9260.9 21.1%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.1 461.2%   
Return on assets %5.414.1 38.6%  
Return on equity %6.815.0 45.4%  
Return on capital %11.515.2 75.8%  
Exports to sales %01.5 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA19 0.0%   
Imports (cif) Rs mNA263 0.0%   
Fx inflow Rs m5819 296.9%   
Fx outflow Rs m1,326264 502.7%   
Net fx Rs m-1,269-244 519.1%   
CASH FLOW
From Operations Rs m-1,943236 -823.9%  
From Investments Rs m2,742-224 -1,224.2%  
From Financial Activity Rs m-298-27 1,121.1%  
Net Cashflow Rs m501-15 -3,387.2%  

Share Holding

Indian Promoters % 0.0 64.0 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 0.2 1,000.0%  
FIIs % 1.6 9.7 16.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 26.1 82.4%  
Shareholders   41,647 54,701 76.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   SUVEN LIFESCIENCES  SHASUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  SUN PHARMA  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 202 Points Lower; Power and Metal Stocks Witness Selling(Closing)

Indian share markets witnessed most of the selling pressure during closing hours today and ended lower.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Buy this 'Crorepati Stock' and You Could End Up Stinking Rich(Profit Hunter)

Feb 5, 2020

I'm talking about an individual small cap stock that could go up so many times that they make their investors stinking rich in the process. You definitely want to know more...

This Smallcap Stock Could be the Next Titan (Up 1,400% in 10 Years)(Profit Hunter)

Feb 11, 2020

A blueprint to latch on to the next 'Crorepati' stock - and an event I hope you won't miss on any account.

How to Prevent the Market from Taking Your Money(Fast Profits Daily)

Feb 3, 2020

Watch out! These are times when the market will try to fool you.

Will Your Trade Go Up or Down Today?(Fast Profits Daily)

Feb 5, 2020

How you can find out which way your trade is likely to move on any given trading day.

A Quantum Budget?(The Honest Truth)

Feb 3, 2020

Ajit Dayal on the Union Budget 2020-21.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Feb 14, 2020 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS